DekaBank Deutsche Girozentrale raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 6.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,254 shares of the company's stock after acquiring an additional 2,609 shares during the quarter. DekaBank Deutsche Girozentrale's holdings in Teva Pharmaceutical Industries were worth $307,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Teva Pharmaceutical Industries by 3.7% during the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company's stock worth $391,081,000 after acquiring an additional 1,494,814 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 9.5% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 21,380,200 shares of the company's stock valued at $172,533,000 after purchasing an additional 1,847,280 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 8.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 18,962,766 shares of the company's stock worth $138,282,000 after purchasing an additional 1,424,200 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 23.5% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 14,132,727 shares of the company's stock worth $114,051,000 after buying an additional 2,685,200 shares in the last quarter. Finally, Credit Suisse AG boosted its stake in Teva Pharmaceutical Industries by 2.0% during the second quarter. Credit Suisse AG now owns 6,894,374 shares of the company's stock valued at $51,847,000 after buying an additional 137,322 shares during the last quarter. 50.39% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 1.1 %

TEVA opened at $10.38 on Friday. The business has a fifty day moving average of $9.51 and a 200 day moving average of $9.10. The company has a debt-to-equity ratio of 1.94, a quick ratio of 0.66 and a current ratio of 0.99. Teva Pharmaceutical Industries Limited has a 52-week low of $6.78 and a 52-week high of $11.44.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of research reports. StockNews.com began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They issued a "buy" rating on the stock. Piper Sandler reduced their target price on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, November 23rd. UBS Group cut shares of Teva Pharmaceutical Industries from a "neutral" rating to a "sell" rating in a research report on Friday, November 4th. BMO Capital Markets dropped their price target on Teva Pharmaceutical Industries from $11.00 to $10.00 and set a "market perform" rating for the company in a research report on Monday, November 7th. Finally, JPMorgan Chase & Co. downgraded Teva Pharmaceutical Industries from a "neutral" rating to an "underweight" rating and decreased their price objective for the company from $11.00 to $10.00 in a research report on Monday, November 14th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Hold" and a consensus price target of $10.67.

About Teva Pharmaceutical Industries

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Further Reading

• Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.